Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Co.'s programs include: Levosimendan, which is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib (marketed in the U.S. as Gleevec®), which is a tyrosine kinase inhibitor.
|
Free TENX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |